EGFR and non-small cell lung carcinoma: A retrospective study evaluating the effect of ICI monotherapy in advanced NSCLC found marked differences in PFS and OS between different EGFR-mutant subgroups, with exon 21-mutated tumors showing more favorable outcomes than those with exon 19 or T790M mutations.